MarketCap
Facebook
X
Telegram
Rezolute Interest Expense | RZLT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Rezolute
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 375 K | - | 4.96 M | 689 K | 1.6 K | 5.04 K | 6.73 K | 4.23 M | 569 K | - | 204 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.96 M | 1.6 K | 1.23 M |
Quarterly Interest Expense Rezolute
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.8 K | 1.29 M | 911 K | 1.29 M | 912 K | 147 | - | 147 | - | - | 1.6 K | - | 1.6 K | 1.38 K | 1.61 K | 1.38 K | 1.61 K | 2.3 K | 500 | 2.3 K | 500 | 623 K | 165 K | 623 K | 165 K | 109 K | 105 K | - | 91.7 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 147 | 264 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
-1 K | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
3.26 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
5.78 M | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
53 K | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-309 K | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
61 K | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.25 M | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
17.3 M | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
-43 K | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
14.2 M | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
1.12 M | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
99.1 M | $ 3.63 | 3.93 % | $ 795 M | Britain |
 |
G1 Therapeutics
GTHX
|
-5.32 M | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
-1.5 M | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
Codexis
CDXS
|
-4.81 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
3.02 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
2.89 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
2.92 M | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
9 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
3.74 M | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
927 K | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
Cellectar Biosciences
CLRB
|
-426 | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
-20 K | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
348 K | - | - | $ 123 M | USA |
 |
Cocrystal Pharma
COCP
|
-640 K | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-357 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
19.3 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Chimerix
CMRX
|
8.18 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.24 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
890 K | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
1.4 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
|
Champions Oncology
CSBR
|
211 K | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
100 K | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
649 K | $ 1.72 | 2.38 % | $ 13.8 M | USA |